Copenhagen, 2014-10-31 09:48 CET (GLOBE NEWSWIRE) -- Copenhagen, 31 October 2014 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) will announce its Interim Report for the first nine months of 2014 on Friday, 7 November 2014, in accordance with the company’s financial calendar. The report is expected to be approved and released in the morning before the start of trading hours on Nasdaq Copenhagen.
Conference call – Friday, 7 November at 2 pm CET/ 8am EDT
On the day of release, Zealand will host a conference call at 2p CET/ 8am EDT. On the call, David Solomon, President and Chief Executive Officer, Mats Blom, Chief Financial Officer, and Hanne Leth Hillman, Vice President and Head of IR and Corporate Communications, will present the interim report, which will be followed by a Q&A session.
The conference call will be conducted in English and the dial-in numbers are:
DK standard access +45 3272 8018
UK and international +44 (0) 1452 555131
US (free dial-in) +1 866 682 8490
A live audio cast of the call including an accompanying slide presentation will be available via the following link, http://www.media-server.com/m/p/awksiczn, which can also be accessed from the front page of Zealand’s website (www.zealandpharma.com). Participants in the audio cast are advised to register approximately 10 minutes before the start.
A replay of the event will be available from the Investor section of Zealand’s website following the call.
***
For further information, please contact:
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines, in-house competences in clinical trial design and management and a therapeutic focus on cardio-metabolic diseases. The company has a broad portfolio of therapeutic products – proprietary and partnered.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed world-wide ex-US as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for both products is planned for 2015 ─ summer for Lyxumia® and as early as end 2015 for LixiLan.
Zealand is advancing a pipeline of proprietary, next-generation therapies, including danegaptide (prevention of Ischemic Reperfusion Injury) in addition to several preclinical programs. Partnering represents an important component of strategy to share development risk in large clinical trials, to provide funding and to commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Boehringer Ingelheim, Helsinn Healthcare and Lilly,
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
